Skip to main content

Table 4 Relevance evaluation standard between AE and investigational drugs

From: A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial

Judgment results

Judgment Index

â‘ 

â‘¡

â‘¢

â‘£

⑤

Definite relevance

+

+

--

+

+

Probable relevance

+

+

--

+

?

Difficult to determine

+

+

±

±

?

Probable irrelevance

+

--

±

±

?

Definite irrelevance

--

--

+

--

--

  1. AE Judgment Index: ① Whether or not there is a successive relationship between time of treatment onset and time of AE occurrence. ② Whether or not suspicious AE is in accordance with the known AE of the medicine. ③ Whether or not the suspicious AE can be explained by the effect of combination of medicine, patient’s clinical condition, or other therapies. ④ Whether or not suspicious AE disappears or is relieved after drug withdrawal or dosage reduction. ⑤ Whether or not similar reactions occur after using the suspicious drugs again
  2. + means affirmative, --means negative, ± means difficult to determine, ? means unclear situation
  3. 1- Definite relevance, 2-Probable relevance, 3-Difficult to determine, 4-Probable irrelevance, 5-Definite irrelevance
  4. The incidence of ADR is calculated by using the sum of the cases of 1 + 2 + 3 as numerator, and the number of all cases as denominator